Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2017

View Archived Issues

Cytovation raises funds to advance CyPep-1

Ultupharma divulges novel antibacterials

Sunshine Lake Pharma presents novel RNA-directed RNA polymerase inhibitors

Phase I/II data on EPI-506 presented for the treatment of mCRPC

FDA grants orphan drug designation for ALM-201 for the treatment of ovarian cancer

Celgene's CC-220 shows promise in phase II SLE study

Bayer initiates phase III ASTEROID study program of vilaprisan

Pralia approved for additional indication in Japan

Novartis files application in Japan to expand approval of Signifor

Vanucizumab trial suggests ANG-2 is not a relevant target in metastatic colorectal cancer

Swedish Orphan Biovitrum's SOBI-003 receives U.S. orphan status for MPS type III A

FDA grants glasdegib orphan designation for acute myeloid leukemia

Phase I data presented for AMG-232 in metastatic cutaneous melanoma

Novartis' Jadenu approved in Japan

Synspira raises funds to advance cystic fibrosis candidate into clinic

Angle reports topline data from Parsortix pelvic mass studies

Acer Therapeutics enters merger agreement with Opexa Therapeutics

Mitsubishi Tanabe Pharma obtains approval in Japan for Canalia combination tablets

Human neural stem cells show disease-modifying activity in Huntington's disease model

Antisense oligonucleotide QRX-411 named FDA orphan drug for retinitis pigmentosa

Spanish antitrust approval for Norgine's acquisition of Merus Labs

SOX4 found to be a poor prognostic marker in acute myeloid leukemia

Japan's MHLW approves Olumiant for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...